Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

RET inhibitor

DRUG CLASS:

RET inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Oncocytic Carcinoma	No biomarker	Thyroid Gland Oncocytic Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1